Shenqi Xingnao Granules ameliorates cognitive impairments and Alzheimer's disease-like pathologies in APP/PS1 mouse model

被引:0
|
作者
Cui-cui Yang [1 ]
Xiao-yu Jia [1 ]
Li Zhang [1 ]
Ya-li Li [1 ]
Zhan-jun Zhang [2 ,3 ]
Lin Li [1 ]
Lan Zhang [1 ]
机构
[1] Department of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing Institute for Brain Disorders, Beijing Engineering Research Center for Nerve System Drugs,Key Laboratory for Neurodegenerative Diseases of Ministry of Education
[2] State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University
[3] BABRI Centre, Beijing Normal University
关键词
D O I
暂无
中图分类号
R285.5 [中药实验药理];
学科分类号
1008 ;
摘要
Objective:Alzheimer’s disease(AD) is along with cognitive decline due to amyloid-β(Aβ) plaques,tau hyperphospho rylation,and neuron loss.Shenqi Xingnao Granules(SQXN),a traditional Chinese medicine,significantly ameliorated the cognitive function and daily living abilities of patients with AD.However,till date,no study has investigated the mechanism of action of SQXN on AD.The present study aimed to verify the effects of SQXN treatment on cognitive impairments and AD-like pathologies in APP/PS1 mice.Methods:Four-month-old APP/PS1 transgenic(Tg) mice were randomly divided into a model group and SQXN-treated(3.5,7,14 g/kg per day) groups.Learning-memory abilities were determined by Morris water maze and object recognition test.All mice were sacrificed and the brain samples were collected after 75 d.The soluble Aβ contents were detected by Elisa kit;The levels of expression of NeuN,APP,phosphorylated tau and related protein were measured by Western blotting;The inflammation factors were detected by the proinflammatory panel kit.Results:Four-month-old APP/PS1 mice were administered SQXN by oral gavage for 2.5 months.Using the Morris water maze tests and Novel object recognition,we found that SQXN restored behavioral deficits in the experimental group of Tg mice when compared with the controls.SQXN also inhibited neuronal loss(NeuN marker).SQXN treatment decreased soluble Aβ42 through inhibiting the expression of sAPPβ and BACE-1 without regulating full-length amyloid precursor protein(FL APP).Insulin degrading enzyme(IDE),the Aβ degrading enzyme,were increased by SQXN.In addition,SQXN reduced hyperphosphorylated tau protein levels and prevented excessive activation of p-GSK-3β in the brain of APP/PS1 mice.Compared with APP/PS1 transgenic negative mice,IFN-γ,IL-1β,IL-2,IL-4,IL-5,IL-6,IL-12 p70,KC/GRO and TNF-α were not obviously changed in the brain of 6.5-month-old APP/PS1 transgenic(Tg) mice.However,SQXN could inhibited the expression of IL-2.Conclusion:These results demonstrate that SQXN ameliorates the cognitive impairments in APP/PS1 mice.The possible mechanisms involve its inhibition of neuronal loss,soluble Aβ deposition,tau hyperphosphorylation and inflammation.
引用
收藏
页码:421 / 429
页数:9
相关论文
共 50 条
  • [31] Liuwei Dihuang Decoction improves cognitive impairments via regulating immune system in APP/PS1 transgenic mouse,a mouse model of Alzheimer disease
    Xi LEI
    Jian-hui WANG
    Xiao-rui CHENG
    Xiao-rui ZHANG
    Gang LIU
    Jun-ping CHENG
    Wen-xia ZHOU
    Yong-xiang ZHANG
    中国药理学与毒理学杂志, 2018, 32 (04) : 291 - 291
  • [32] Characterization of the APP/PS1 mouse model of Alzheimer's disease in senescence accelerated background
    Lok, Kenghoe
    Zhao, Hong
    Shen, Hanlin
    Wang, Zejian
    Gao, Xiang
    Zhao, Wenjuan
    Yin, Ming
    NEUROSCIENCE LETTERS, 2013, 557 : 84 - 89
  • [33] Alterations of GABA B receptors in the APP/PS1 mouse model of Alzheimer's disease
    Salazar, Arnold M.
    Leisgang, Amanda M.
    Ortiz, Andrew A.
    Murtishaw, Andrew S.
    Kinney, Jefferson W.
    NEUROBIOLOGY OF AGING, 2021, 97 : 129 - 143
  • [34] Impact of chronic doxycycline treatment in the APP/PS1 mouse model of Alzheimer's disease
    Gomez-Murcia, Victoria
    Carvalho, Kevin
    Thiroux, Bryan
    Caillierez, Raphaelle
    Besegher, Melanie
    Sergeant, Nicolas
    Buee, Luc
    Faivre, Emile
    Blum, David
    NEUROPHARMACOLOGY, 2022, 209
  • [35] Sex differences in vascular reactivity of APP/PS1 mouse model of Alzheimer's disease
    Schweitzer, N.
    Cover, C.
    Wu, M.
    Aizenstein, H.
    Vazquez, A.
    Iordanova, B.
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2022, 42 (1_SUPPL): : 25 - 25
  • [36] High throughput multiorgan metabolomics in the APP/PS1 mouse model of Alzheimer's disease
    Gonzalez-Dominguez, Raul
    Garcia-Barrera, Tamara
    Vitorica, Javier
    Luis Gomez-Ariza, Jose
    ELECTROPHORESIS, 2015, 36 (18) : 2237 - 2249
  • [37] Calpain Inhibitor Calpeptin Improves Alzheimer's Disease-Like Cognitive Impairments and Pathologies in a Diabetes Mellitus Rat Model
    Li, Min
    Zhou, Siqi
    Wang, Gege
    Qiao, Luyao
    Yi, Shouqin
    Li, Tianpei
    Pan, Xin
    Liu, Xu
    Tang, Zhenyu
    NEUROTOXICITY RESEARCH, 2022, 40 (05) : 1248 - 1260
  • [38] Alzheimer's Disease-like Pathologies and Cognitive Impairments Induced by Formaldehyde in Non-Human Primates
    Zhai, Rongwei
    Rizak, Joshua
    Zheng, Na
    He, Xiaping
    Li, Zhenhui
    Yin, Yong
    Su, Tao
    He, Yingge
    He, Rongqiao
    Ma, Yuanye
    Yang, Meifeng
    Wang, Zhengbo
    Hu, Xintian
    CURRENT ALZHEIMER RESEARCH, 2018, 15 (14) : 1304 - 1321
  • [39] Urinary and faecal metabolic characteristics in APP/PS1 transgenic mouse model of Alzheimer's disease with and without cognitive decline
    Zheng, Yafei
    Xu, Qingqing
    Jin, Qihao
    Du, Yao
    Yan, Junjie
    Gao, Hongchang
    Zheng, Hong
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2022, 604 : 130 - 136
  • [40] Seizure susceptibility in the APP/PS1 mouse' model of Alzheimer's disease and relationship with amyloid β plaques
    Reyes-Marin, Karen E.
    Nunez, Angel
    BRAIN RESEARCH, 2017, 1677 : 93 - 100